GlassScriptPhysician profile
Tyler C Free
NPI 1508943846
$2,714.56
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $464 · 2022: $484 · 2023: $813 · 2024: $952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,765.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $548.50 | 2021-2024 | |
| Novo Nordisk INC | $261.53 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $219.72 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Gilead Sciences, INC. | $144.72 | 2021-2024 | Descovy |
| Horizon Therapeutics Plc | $114.42 | 2021-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $109.03 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Antares Pharma, INC. | $97.08 | 2022-2024 | Xyosted, Tlando, Nocdurna |
| Novartis Pharmaceuticals Corporation | $92.96 | 2022-2024 | |
| Sanofi Pasteur INC. | $90.70 | 2023 | |
| Janssen Pharmaceuticals, INC | $74.88 | 2022-2024 | Spravato |
| Agile Therapeutics, INC. | $73.83 | 2023-2024 | Twirla |
| Sanofi-Aventis U.S. LLC | $66.47 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.35 | 2022-2023 | Xifaxan |
| Corium, LLC | $51.60 | 2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $48.40 | 2021-2024 | Trintellix |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Free listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.